Drugs / PepGNP-COVID19
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07183709 | Feb → Oct 2026 expected | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05113862 | Jan → Sep 2022 | COVID-19 | Gylden Pharma Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05633446 | Sep 2025 → Jun 2026 overdue | COVID-19 | Gylden Pharma Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PepGNP-Covid19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05113862 ↗ |
| Modality | Vaccine | “A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells” PMID 40197245 ↗ Apr 2025 |
| Route | Other | “Two intradermal injections in the upper arm spaced 21 days apart” NCT05113862 ↗ |